+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030

  • ID: 4806526
  • Report
  • Region: Global
  • 800 Pages
  • Roots Analysis
1 of 3

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Brace Pharma Capital
  • Fudan University
  • Lion TCR
  • Piper Jaffray
  • Tekla Capital Management
  • MORE

The cancer therapeutics market is considered to be one of the most active segments within the pharmaceutical industry. In the past five years, the USFDA has approved more than 100 drugs for the treatment of different types of cancer. However, there is still a pressing need for more specific and potent drugs/therapies to combat this complex, life-threatening clinical condition. It is also worth highlighting that, in the coming years, the number of cancer patients is anticipated to increase substantially along with the growing global population. According to the International Agency for Research on Cancer (IARC), close to 17 million new cases of cancer were diagnosed in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years.

Among the current initiatives focused on developing targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. With the recent approval of KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences) for the treatment of CD19-positive relapsed / refractory leukaemias and lymphomas, such ACTs have become a part of mainstream healthcare solutions.

Encouraging clinical trial results and therapeutic response rates achieved across various haematological cancers and solid tumours have further inspired research groups to focus their efforts on the development of these novel therapies. So far, more than 150 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential therapy candidates. In fact, multiple collaborations have been inked in the past decade between various therapy developers and academic / research institutes to advance the development of various pipeline candidates. The ongoing research activity in this field has also led to the discovery of several novel molecular targets. Further research and characterization of the aforementioned targets have significantly strengthened the research pipelines of companies engaged in this market. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised for success in the long-run as multiple product candidates are expected to be approved over the coming decade.

Scope of the Report

The “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). The report highlights the efforts of both industry players and academic organizations. Amongst other elements, the report features the following:

  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to the type of therapy, type of developer (industry / non-industry), phase of development, target therapeutic indication(s), key target antigen(s), source of T-cells (autologous/allogenic), and route of administration. In addition, we have provided an overview of the competitive landscape, key challenges and anticipated future trends associated with CAR-T, TCR and TIL-based therapies.
  • Comprehensive profiles of marketed and mid to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • A detailed analysis highlighting several key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists/researchers involved in the development of T-cell therapies.
  • An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers. Further, it includes a relative competitiveness analysis of different T-cell immunotherapy-based gene-editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary T-cell based products/technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs. It presents a detailed analysis of the approved / pipeline products in this domain, including information on the current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models/approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report includes potential sales forecasts of T-cell immunotherapies that are currently marketed or are in late stages of development. Additionally, it provides forecasts for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain.

The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Brace Pharma Capital
  • Fudan University
  • Lion TCR
  • Piper Jaffray
  • Tekla Capital Management
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.7. Other Important Biological Targets for CAR Development
3.7.8. Challenges Associated with CAR-T Cell Therapies
3.7.8.1. Competitive Risks
3.7.8.2. Clinical Risks
3.7.8.3. Regulatory Risks
3.7.8.4. Commercial Risks
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. History of Development
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR for Therapy
3.8.4. Differences between CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. History of Development
3.9.2. Development of TILs for Therapy
3.10. Key Challenges and Roadblocks

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. T-Cell Immunotherapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: Overall Market Overview
5.2.1. Analysis by Type of Product
5.2.2. Analysis by Type of Developer
5.2.3. Analysis by Phase of Development
5.2.4. Analysis by Target Oncological Indications
5.2.4.1. CAR-T Cell Immunotherapies: Popular Target Indications
5.2.4.2. TCR-based Immunotherapies: Popular Target Indications
5.2.4.3. TIL-based Immunotherapies: Popular Target Indications
5.2.5. Analysis by Popular Target Antigens (CAR-T Cell Therapies and TCR-based Therapies)
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Key Industry Players: Analysis by Number of Therapies in Development
5.2.9. Key Non-Industry Players: Analysis by Number of Therapies in Development

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Immunotherapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Immunotherapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Immunotherapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Immunotherapies
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Immunotherapies
6.2.2.2. Clinical Trial Results of Prominent of Meso CAR-T Cell Immunotherapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Immunotherapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Immunotherapies
6.3. T-Cell Immunotherapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.3.3. TCR-based Therapies: Key Opinion Leaders
6.3.4. TCR-based Therapies: Most Prominent Key Opinion Leaders
6.3.5. TIL-based Therapies: Key Opinion Leaders
6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders
6.4. T-Cell Immunotherapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
8.3. YESCARTA®/ Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.1.1. JCAR014
8.4.1.2. JCAR017
8.4.1.3. JCAR018
8.4.1.4. JCAR020
8.4.1.5. JCAR023
8.4.1.6. JCAR024
8.4.1.7. JCARH125
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen and Manufacturing
8.5. bb2121 (bluebird bio / Celgene)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Trial Results
8.5.4. Dosage Regimen and Manufacturing
8.6. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. CD19 CAR-T Cell Therapy (Takara Bio)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. Dual Targeting CAR-T Cell Therapy (Autolus)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing
8.9. CAR-T Cell Therapies (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Dosage Regimen and Manufacturing

9. TCR-BASED THERAPY PROFILES
9.1. Chapter Overview
9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
9.2.1. Therapy Overview
9.2.1.1. SPEAR T-Cells Technology Platform
9.2.1.1. NY-ESO SPEAR T-Cell Therapy
9.2.1.2. MAGE-A10 T-Cell Therapy
9.2.1.3. MAGE-A4 T-Cell Therapy
9.2.1.4. AFP T-Cell Therapy
9.2.2. Current Development Status
9.2.3. Key Clinical Trial Results
9.2.4. Dosage Regimen and Manufacturing
9.3. IMCgp100 (Immunocore)
9.3.1. Therapy Overview
9.3.2. Current Development Status
9.3.3. Key Clinical Trial Results
9.3.4. Dosage Regimen and Manufacturing
9.4. ALT-801 (Altor BioScience)
9.4.1. Therapy Overview
9.4.2. Current Development Status
9.4.3. Key Clinical Trial Results
9.4.4. Dosage Regimen
9.4.5. Patent Portfolio
9.5. JTCR016 (Juno Therapeutics)
9.5.1. Therapy Overview
9.5.2. Current Development Status
9.5.3. Key Clinical Trial Results
9.5.4. Dosage Regimen and Manufacturing
9.6. CMD-602 / WT1 TCR Therapy (Cell Medica)
9.6.1. Therapy Overview
9.6.2. History of Development
9.6.3. Current Development Status
9.6.4. Key Clinical Trial Results
9.6.5. Dosage Regimen and Manufacturing
9.7. TBI-1301 (Takara Bio)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing

10. TIL-BASED THERAPY PROFILES
10.1. Chapter Overview
10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
10.2.1. Therapy Overview
10.2.2. Current Development Status
10.2.2.1. LN-144
10.2.2.2. LN-145
10.2.3. Key Clinical Trial Results
10.2.4. Dosage Regimen and Manufacturing
10.2.5. Patent Portfolio
10.3. TIL (Nantes University Hospital)
10.3.1. Therapy Overview
10.3.2. Current Development Status
10.3.3. Key Clinical Trial Results
10.3.4. Dosage Regimen and Manufacturing
10.3.5. Patent Portfolio
10.4. TIL (Netherlands Cancer Institute)
10.4.1. Therapy Overview
10.4.2. Current Development Status
10.4.3. Key Clinical Trial Results
10.4.4. Dosage Regimen and Manufacturing
10.4.5. Patent Portfolio

11. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
11.1. Chapter Overview
11.2. Haematological Malignancies
11.2.1. Leukaemia and Lymphoma
11.2.1.1. Leukaemia: Introduction and Epidemiology
11.2.1.1.1. Acute Myeloid Leukemia (AML)
11.2.1.1.2. Chronic Myeloid Leukemia (CML)
11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
11.2.1.2. Lymphoma: Introduction and Epidemiology
11.2.1.3. Current Treatment Landscape
11.2.1.3.1. Targeted Therapies
11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
11.2.1.4.3. TIL-based Therapies and Leukemia
11.2.2. Multiple Myeloma
11.2.2.1. Introduction and Epidemiology
11.2.2.2. Current Treatment Landscape
11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3. Solid Tumors
11.3.1. Metastatic Melanoma
11.3.1.1. Introduction and Epidemiology
11.3.1.2. Current Treatment Landscape
11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma
11.3.2. Lung Cancer
11.3.2.1. Introduction and Epidemiology
11.3.2.2. Current Treatment Landscape
11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3. Pancreatic Cancer
11.3.3.1. Introduction and Epidemiology
11.3.3.2. Current Treatment Landscape
11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer
11.3.4. Liver Cancer
11.3.4.1. Current Treatment Landscape
11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.4.3. CAR-T Cell Therapies and Liver Cancer
11.3.4.3.1. TCR-based Therapies and Liver Cancer
11.3.4.3.2. TIL-based Therapies and Liver Cancer
11.3.5. Breast Cancer
11.3.5.1. Introduction and Epidemiology
11.3.5.2. Current Treatment Landscape
11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
11.3.5.3.2. TCR-based Therapies and Breast Cancer
11.3.5.3.3. TIL-based Therapies and Breast Cancer
11.3.6. Ovarian Cancer
11.3.6.1. Introduction and Epidemiology
11.3.6.2. Current Treatment Landscape
11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
11.3.6.3.3. TIL-based Therapies and Ovarian Cancer
11.3.7. Bladder Cancer
11.3.7.1. Introduction and Epidemiology
11.3.7.2. Current Treatment Landscape
11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.8. Kidney Cancer
11.3.8.1. Introduction and Epidemiology
11.3.8.2. Current Treatment Landscape
11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape

12. EMERGING TECHNOLOGIES
12.1. Chapter Overview
12.2. Genome Editing Technologies
12.2.1. Applications of Genome Editing Technologies
12.2.2. Emerging Technology Platforms for T-Cell Therapy Development and Production
12.2.2.1. CRISPR / Cas9 System
12.2.2.1.1. Key Components and Function
12.2.2.1.2. Mechanism of Action
12.2.2.1.3. Targeting Efficiency and Challenges
12.2.2.1.4. Next-GEN CRISPR Technology
12.2.2.1.5. Technology Providers
12.2.2.1.5.1. Editas Medicine
12.2.2.1.5.2. Intellia Therapeutics
12.2.2.1.5.3. CRISPR Therapeutics
12.2.2.1.5.4. Beam Therapeutics
12.2.2.1.5.5. Gracell Biotechnologies
12.2.2.2. TALENs
12.2.2.2.1. Key Components and Function
12.2.2.2.2. Mechanism of Action
12.2.2.2.3. Advantages and Challenges
12.2.2.2.4. Technology Providers
12.2.2.2.4.1. Cellectis
12.2.2.2.4.2. Editas Medicine
12.2.2.3. megaTAL
12.2.2.3.1. Technology Providers
12.2.2.3.1.1. bluebird bio
12.2.2.4. Zinc Finger Nuclease
12.2.2.4.1. Technology Providers
12.2.2.4.1.1. Sangamo Therapeutics
12.3. Designing T-Cell Therapies with Improved Characteristics
12.3.1. Technologies for Targeting Multiple Types of Cancers
12.3.1.1. Antibody Coupled T-Cell Receptor
12.3.1.1.1. Unum Therapeutics
12.3.1.2. NKR-T Platform
12.3.1.2.1. Celyad
12.3.1.2.2. Glycostem
12.3.2. Technologies for Improving Therapeutic Safety
12.3.2.1. Armored CAR and EGFRt Technology
12.3.2.1.1. Juno Therapeutics
12.3.2.2. RheoSwitch Therapeutic System
12.3.2.2.1. Intrexon
12.3.2.3. Inducible Caspase 9 Safety Switch
12.3.2.3.1. Bellicum Pharmaceuticals
12.3.2.3.1.1. CaspaCIDe® Technology
12.3.2.3.1.2. CIDeCAR® Technology
12.3.2.3.1.3. GoCAR-T® Technology
12.3.2.4. On-Off Switch, Multiple Companies
12.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
12.3.2.4.2. On-Off Switch (Theravectys)
12.3.3.5. Other Technologies to Improve CAR-T Safety
12.3.3.6. Allogeneic Technologies
12.3.3.6.1. CIK CAR-T™ Cells (Formula Pharmaceuticals)
12.3.3.6.2. Allogeneic Platform (Celyad)
12.3.3.6.3. Allogeneic Platform (Cellectis)

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. T-Cell Immunotherapies: List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Type of Partnership and Type of Product
13.3.4. Analysis by Type of Industry and Type of Product
13.3.5. Analysis by Individual Products
13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
13.3.9. Regional Analysis
13.3.10. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. T-Cell Immunotherapies: Funding and Investment Analysis
14.3.1. Analysis by Number of Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Amount Invested across Different Types of Therapies
14.3.5. Most Active Players: Analysis by Number of Instances
14.3.6. Most Active Investors: Analysis by Number of Instances
14.3.7. Regional Analysis

15. OTHER T-CELL IMMUNOTHERAPIES
15.1. Chapter Overview
15.2. Other T-Cell Immunotherapies
15.2.1. Analysis by Phase of Development
15.2.2. Analysis by Target Therapeutic Area
15.2.3. Analysis by Type of Cells
15.2.4. Analysis by Source of T-Cells
15.3. Treg Cell Therapy
15.3.1. Caladrius Biosciences
15.3.2. TRACT Therapeutics
15.3.3. Cellenkos
15.3.4. Other Companies
15.4. T-Cell-based Vaccines
15.4.1. Immunovative Therapies
15.4.2. TVAX Biomedical
15.5. Virus-Driven T-Cell Therapy
15.5.1. Atara Biotherapeutics
15.5.2. bluebird bio
15.5.3. Cell Medica
15.5.4. Eutilex
15.5.5. Tessa Therapeutics
15.5.6. ViGenCell
15.6. Fucosylated T-Cell Therapy
15.6.1. Targazyme
15.7. PD-1 Knockout Engineered T-Cell Therapy
15.7.1. Chengdu MedGenCell
15.7.2. Anhui Kedgene Biotechnology
15.8. TAC-T Cell Therapy
15.8.1. Triumvira Immunologics
15.9. Gama Delta T-Cell Therapy
15.9.1. GammaCell Bio-Technologies
15.9.2. TC Biopharm

16. CASE STUDY: CELL THERAPY MANUFACTURING
16.1. Chapter Overview
16.2. Cell Therapy Manufacturing
16.3. Cell Therapy Manufacturing Models
16.3.1. Centralized Manufacturing
16.3.2. Decentralized Manufacturing
16.4. Scalability of Cell Therapy Manufacturing Processes
16.4.1. Scale-up
16.4.2. Scale-out
16.5. Types of Cell Therapy Manufacturers
16.6. Key Challenges Related to Manufacturing Cell Therapies
16.7. Important Factors for Cell Therapy Manufacturing
16.7.1. Cell Characterization
16.7.2. Cost of Goods
16.8. Automation of Cell Therapy Manufacturing Processes
16.9. Cell Therapy Manufacturing Supply Chain
16.10. Companies with In-House Capabilities
16.11. Contract Manufacturers
16.12. Regulatory Landscape

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell / Gene Therapies
17.3. Pricing Models for T-Cell Immunotherapies
17.3.1. Based on Associated Costs
17.3.2. Based on Availability of Competing Products
17.3.3. Based on Patient Segment
17.3.4. Based on the Opinions of Industry Experts
17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
17.4.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope and Limitations
18.3. Key Assumptions and Forecast Methodology
18.4. Overall T-Cell Immunotherapies Market, 2019-2030
18.4.1. T-Cell Immunotherapies Market: Distribution by Type of Therapy
18.4.2. T-Cell Immunotherapies Market: Distribution by Target Indication
18.4.3. T-Cell Immunotherapies Market: Distribution by Target Antigen
18.4.4. T-Cell Immunotherapies Market: Distribution by Key Players
18.4.5. T-Cell Immunotherapies Market: Distribution by Geography
18.5. T-Cell Immunotherapies Market: Value Creation Analysis
18.6. Overall CAR-T Cell Therapies Market, 2019-2030
18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
18.6.3. CAR-T Cell Therapies Market: Distribution by Key Players
18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
18.6.5. Product Wise Sales Forecast
18.6.5.1. KYMRIAH® (Novartis)
18.6.5.1.1. Target Patient Population
18.6.5.1.2. Sales Forecast (USD Million)
18.6.5.1.3. Net Present Value (USD Million)
18.6.5.1.4. Value Creation Analysis
18.6.5.2. YESCARTA® (Gilead Sciences)
18.6.5.2.1. Target Patient Population
18.6.5.2.2. Sales Forecast (USD Million)
18.6.5.2.3. Net Present Value (USD Million)
18.6.5.2.4. Value Creation Analysis
18.6.5.3. bb2121 (bluebird bio / Celgene)
18.6.5.3.1. Target Patient Population
18.6.5.3.2. Sales Forecast (USD Million)
18.6.5.3.3. Net Present Value (USD Million)
18.6.5.3.4. Value Creation Analysis
18.6.5.4. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
18.6.5.4.1. Target Patient Population
18.6.5.4.2. Sales Forecast (USD Million)
18.6.5.4.3. Net Present Value (USD Million)
18.6.5.4.4. Value Creation Analysis
18.6.5.5. MB-CART19.1 (Miltenyi Biotec)
18.6.5.5.1. Target Patient Population
18.6.5.5.2. Sales Forecast (USD Million)
18.6.5.5.3. Net Present Value (USD Million)
18.6.5.5.4. Value Creation Analysis
18.6.5.6. CD19 CAR-T (Sinobioway Cell Therapy)
18.6.5.6.1. Target Patient Population
18.6.5.6.2. Sales Forecast (USD Million)
18.6.5.6.3. Net Present Value (USD Million)
18.6.5.6.4. Value Creation Analysis
18.6.5.7. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec)
18.6.5.7.1. Target Patient Population
18.6.5.7.2. Sales Forecast (USD Million)
18.6.5.7.3. Net Present Value (USD Million)
18.6.5.7.4. Value Creation Analysis
18.6.5.8. AUTO2 (Autolus)
18.6.5.8.1. Target Patient Population
18.6.5.8.2. Sales Forecast (USD Million)
18.6.5.8.3. Net Present Value (USD Million)
18.6.5.8.4. Value Creation Analysis
18.6.5.9. AUTO3 (Autolus)
18.6.5.9.1. Target Patient Population
18.6.5.9.2. Sales Forecast (USD Million)
18.6.5.9.3. Net Present Value (USD Million)
18.6.5.9.4. Value Creation Analysis
18.6.5.10. GPC3 CAR-T (Shanghai GeneChem)
18.6.5.10.1. Target Patient Population
18.6.5.10.2. Sales Forecast (USD Million)
18.6.5.10.3. Net Present Value (USD Million)
18.6.5.10.4. Value Creation Analysis
18.6.5.11. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.11.1. Target Patient Population
18.6.5.11.2. Sales Forecast (USD Million)
18.6.5.11.3. Net Present Value (USD Million)
18.6.5.11.4. Value Creation Analysis
18.6.5.12. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.12.1. Target Patient Population
18.6.5.12.2. Sales Forecast (USD Million)
18.6.5.12.3. Net Present Value (USD Million)
18.6.5.12.4. Value Creation Analysis
18.6.5.13. CD19 CAR-T (Shanghai Bioray Laboratory)
18.6.5.13.1. Target Patient Population
18.6.5.13.2. Sales Forecast (USD Million)
18.6.5.13.3. Net Present Value (USD Million)
18.6.5.13.4. Value Creation Analysis
18.6.5.14. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.14.1. Target Patient Population
18.6.5.14.2. Sales Forecast (USD Million)
18.6.5.14.3. Net Present Value (USD Million)
18.6.5.14.4. Value Creation Analysis
18.6.5.15. PCAR-019 (PersonGen BioTherapeutics)
18.6.5.15.1. Target Patient Population
18.6.5.15.2. Sales Forecast (USD Million)
18.6.5.15.3. Net Present Value (USD Million)
18.6.5.15.4. Value Creation Analysis
18.6.5.16. TBI-1501 (Takara Bio)
18.6.5.16.1. Target Patient Population
18.6.5.16.2. Sales Forecast (USD Million)
18.6.5.16.3. Net Present Value (USD Million)
18.6.5.16.4. Value Creation Analysis
18.6.5.17. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology)
18.6.5.17.1. Target Patient Population
18.6.5.17.2. Sales Forecast (USD Million)
18.6.5.17.3. Net Present Value (USD Million)
18.6.5.17.4. Value Creation Analysis
18.6.5.18. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
18.6.5.18.1. Target Patient Population
18.6.5.18.2. Sales Forecast (USD Million)
18.6.5.18.3. Net Present Value (USD Million)
18.6.5.18.4. Value Creation Analysis
18.6.5.19. BinD19 (Shenzhen BinDeBio)
18.6.5.19.1. Target Patient Population
18.6.5.19.2. Sales Forecast (USD Million)
18.6.5.19.3. Net Present Value (USD Million)
18.6.5.19.4. Value Creation Analysis
18.6.5.20. CARCIK-CD19 (Formula Pharmaceuticals)
18.6.5.20.1. Target Patient Population
18.6.5.20.2. Sales Forecast (USD Million)
18.6.5.20.3. Net Present Value (USD Million)
18.6.5.20.4. Value Creation Analysis
18.6.5.21. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
18.6.5.21.1. Target Patient Population
18.6.5.21.2. Sales Forecast (USD Million)
18.6.5.21.3. Net Present Value (USD Million)
18.6.5.21.4. Value Creation Analysis
18.6.5.22. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
18.6.5.22.1. Target Patient Population
18.6.5.22.2. Sales Forecast (USD Million)
18.6.5.22.3. Net Present Value (USD Million)
18.6.5.22.4. Value Creation Analysis
18.7. Overall TCR-based Therapies Market
18.7.1. TCR-based Therapies Market: Distribution by Target Indication
18.7.2. TCR-based Therapies Market: Distribution by Target Antigen
18.7.3. TCR-based Therapies Market: Distribution by Key Players
18.7.4. TCR-based Therapies Market: Distribution by Geography
18.7.6. Product Wise Sales Forecast
18.7.6.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
18.7.6.1.1. Target Patient Population
18.7.6.1.2. Sales Forecast (USD Million)
18.7.6.1.3. Net Present Value (USD Million)
18.7.6.1.4. Value Creation Analysis
18.7.6.2. IMCgp100 (Immunocore)
18.7.6.2.1. Target Patient Population
18.7.6.2.2. Sales Forecast (USD Million)
18.7.6.2.3. Net Present Value (USD Million)
18.7.6.2.4. Value Creation Analysis
18.7.6.3. TBI-1301 (Takara Bio)
18.7.6.3.1. Target Patient Population
18.7.6.3.2. Sales Forecast (USD Million)
18.7.6.3.3. Net Present Value (USD Million)
18.7.6.3.4. Value Creation Analysis
18.7.6.4. ALT-801 (Altor Bioscience)
18.7.6.4.1. Target Patient Population
18.7.6.4.2. Sales Forecast (USD Million)
18.7.6.4.3. Net Present Value (USD Million)
18.7.6.4.4. Value Creation Analysis
18.7.6.5. JTCR016 (Juno Therapeutics)
18.7.6.5.1. Target Patient Population
18.7.6.5.2. Sales Forecast (USD Million)
18.7.6.5.3. Net Present Value (USD Million)
18.7.6.5.4. Value Creation Analysis
18.7.6.6. LioCyx (Lion TCR)
18.7.6.6.1. Target Patient Population
18.7.6.6.2. Sales Forecast (USD Million)
18.7.6.6.3. Net Present Value (USD Million)
18.7.6.6.4. Value Creation Analysis
18.8. Overall TIL-based Therapies Market
18.8.1. TIL-based Therapies Market: Distribution by Target Indication
18.8.3. TIL-based Therapies Market: Distribution by Key Players
18.8.4. TIL-based Therapies Market: Distribution by Geography
18.8.5. Product Wise Sales Forecast
18.8.5.1. TILs (Nantes University Hospital)
18.8.5.1.1. Target Patient Population
18.8.5.1.2. Sales Forecast (USD Million)
18.8.5.1.3. Net Present Value (USD Million)
18.8.5.1.4. Value Creation Analysis
18.8.5.2. TILs (Netherlands Cancer Institute)
18.8.5.2.1. Target Patient Population
18.8.5.2.2. Sales Forecast (USD Million)
18.8.5.2.3. Net Present Value (USD Million)
18.8.5.2.4. Value Creation Analysis
18.8.5.3. Lifileucel (LN-144) (Iovance Biotherapeutics)
18.8.5.3.1. Target Patient Population
18.8.5.3.2. Sales Forecast (USD Million)
18.8.5.3.3. Net Present Value (USD Million)
18.8.5.3.4. Value Creation Analysis
18.8.5.4. LN-145 (Iovance Biotherapeutics)
18.8.5.4.1. Target Patient Population
18.8.5.4.2. Sales Forecast (USD Million)
18.8.5.4.3. Net Present Value (USD Million)
18.8.5.4.4. Value Creation Analysis
18.8.5.5. LTX-315 and TILs (Lytix Biopharma)
18.8.5.5.1. Target Patient Population
18.8.5.5.2. Sales Forecast (USD Million)
18.8.5.5.3. Net Present Value (USD Million)
18.8.5.5.4. Value Creation Analysis

19. PROMOTIONAL ANALYSIS
19.1. Chapter Overview
19.2. Channels used for Promotional Campaigns
19.3. Summary of Product Website Analysis
19.4. Summary of Patient Support Services and Informative Downloads
19.5. KYMRIAH®: Promotional Analysis
19.5.1. Drug Overview
19.5.2. Product Website Analysis
19.5.2.1. Messages for Healthcare Professionals
19.5.2.2. Messages for Patients
19.5.3. Patient Support Services and Informative Downloads
19.5.4. Other Promotional Activities
19.5.4.1. Presence in Conferences
19.6. YESCARTA®: Promotional Analysis
19.6.1. Drug Overview
19.6.2. Product Website Analysis
19.6.2.1. Messages for Healthcare Professionals
19.6.2.2. Messages for Patients
19.6.3. Patient Support Services and Informative Downloads
19.6.4. Other Promotional Activities
19.6.4.1. Presence in Conferences

20. COMPANY PROFILES
20.1. Chapter Overview
20.2. Adaptimmune Therapeutics
20.3. Autolus
20.4. bluebird bio
20.5. CARsgen Therapeutics
20.6. Celgene
20.7. Cell Medica
20.8. Cellectis
20.9. Cellular Biomedicine Group
20.10. Immunocore
20.11. Innovative Cellular Therapeutics
20.12. Iovance Biotherapeutics
20.13. Kite Pharma
20.14. Lion TCR
20.15. Noile-Immune Biotech
20.16. Novartis
20.17. Shanghai GeneChem
20.18. Sinobioway Cell Therapy
20.19. Takara Bio
20.20. Unum Therapeutics
20.21. ZIOPHARM Oncology

21. CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways

22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Cell Therapies
22.2.1 Interview Transcript: Tim Oldham, Chief Executive Officer
22.3. Glycostem Therapeutics
22.3.1 Interview Transcript: Troels Jordansen, Chief Executive Officer
22.4. Gracell Biotechnologies
22.4.1 Interview Transcript: Wei (William) Cao, Chief Executive Officer
22.5. Lion TCR
22.5.1 Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.6. TxCell
22.6.1 Interview Transcript: Miguel Forte, Chief Operating Officer
22.7. Kite Pharma
22.7.1 Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
22.8. Celyad
22.8.1 Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
22.9. Iovance Biotherapeutics
22.9.1 Interview Transcript: Peter Ho, Director, Process Development
22.10. Waisman Biomanufacturing
22.10.1 Interview Transcript: Brian Dattilo, Manager of Business Development
22.11. Theravectys
22.11.1 Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
22.12. Changhai Hospital
22.12.1 Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
22.13. University of Colorado
22.13.1 Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Pillars of Cancer Therapy
Figure 3.2. Difference between Active and Passive Immunotherapies
Figure 3.3. Difference between Specific and Non-Specific Immunotherapies
Figure 3.4. Strategies Employed for the Redirection of T-Cells
Figure 3.5. T-Cell Manufacturing: General Procedure
Figure 3.6. Historical Development of CAR-T cells
Figure 3.7. Structure of Chimeric Antigen Receptor
Figure 3.8. Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9. CAR-T Cell Therapies: Development Process
Figure 3.10. Challenges Associated with CAR-T Cell Therapies
Figure 3.11. TCR-based Therapies: Development Process
Figure 3.12. TIL-based Therapies: Development Process
Figure 3.13. T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1. Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2. Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3. Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4. Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5. Social Media Analysis: Average Number of Likes, Re-tweets and Comments Related to T-cell Immunotherapy
Figure 4.6. Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1. T-Cell Immunotherapies: Analysis by Type of Product
Figure 5.2. T-Cell Immunotherapies: Analysis by Type of Developer
Figure 5.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
Figure 5.4. T-Cell Immunotherapies: Analysis by Phase of Development
Figure 5.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
Figure 5.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 5.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
Figure 5.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
Figure 5.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
Figure 5.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
Figure 5.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
Figure 5.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
Figure 5.13. TCR-based Immunotherapies: Analysis by Target Antigen
Figure 5.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 5.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
Figure 5.16. T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
Figure 5.17. T-Cell Immunotherapies: Analysis by Route of Administration
Figure 5.18. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
Figure 5.19. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.20. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.21. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.22. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
Figure 6.2. T-Cell Immunotherapies: Popular Targets in Solid Tumor
Figure 6.3. CAR-T Cell Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4. CAR-T Cell Immunotherapies: Prominent Key Opinion Leaders
Figure 6.5. TCR-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.6. TCR-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.7. TIL-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.8. TCR-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.9. CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.10. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.11. CAR-Construction: Analysis by Type of Vector
Figure 6.12. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Figure 8.1. Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 10.1. Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 11.1. Leukemia: Classification
Figure 11.2. Leukemia: Global Epidemiological Distribution
Figure 11.3. Lymphoma: Global Epidemiological Distribution
Figure 11.4. Multiple Myeloma: Global Epidemiological Distribution
Figure 11.5. Melanoma: Global Epidemiological Distribution
Figure 11.6. Lung Cancers: Classification
Figure 11.7. Lung Cancer: Global Epidemiological Distribution
Figure 11.8. Pancreatic Cancer: Global Epidemiological Distribution
Figure 11.9. Liver Cancer: Global Epidemiological Distribution
Figure 11.10. Breast Cancer: Global Epidemiological Distribution
Figure 11.11. Ovarian Cancer: Global Epidemiological Distribution
Figure 11.12. Bladder Cancer: Global Epidemiological Distribution
Figure 11.13. Kidney Cancer: Global Epidemiological Distribution
Figure 12.1. Genome Editing Technologies: Applications
Figure 12.2. Genome Editing Technologies Used in T-Cell Therapies
Figure 12.3. Competitiveness Analysis: Genome Editing Technologies
Figure 12.4. Key Technologies to Enhance Features / Characteristics of T-Cell Therapies
Figure 12.5. Cellectis: Properties of Enhanced T-Cell Platform
Figure 12.6. Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 13.1. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
Figure 13.2. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
Figure 13.3. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.4. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Figure 13.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 13.6. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Figure 13.7. Partnerships and Collaborations: Distribution by Type of Industry
Figure 13.8. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
Figure 13.9. Partnerships and Collaborations: Distribution by Individual Products
Figure 13.10. Most Active Industry Players: Distribution by Number of Partnerships
Figure 13.11. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 13.12. Most Active Contract Manufacturers: Distribution by Number of Manufacturing Agreements
Figure 13.13. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Figure 13.14. Partnerships and Collaborations: Regional Distribution
Figure 13.15. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2009-2019
Figure 14.2. Funding and Investment Analysis: Cumulative Amount Invested, Pre-2009-2019 (USD Million)
Figure 14.3. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2009-2019
Figure 14.4. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre-2009-2019 (USD Million)
Figure 14.5. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Figure 14.6. Most Active Players: Distribution by Number of Instances
Figure 14.7. Most Active Investors: Distribution by Number of Instances
Figure 14.8. Funding and Investment Analysis: Distribution by Geography
Figure 15.1. Other T-Cell Immunotherapies: Analysis by Phase of Development
Figure 15.2. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 15.3. Other T-Cell Immunotherapies: Analysis by Type of Cells
Figure 15.4. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 15.5. Treg Cells: Functions
Figure 16.1. Steps for Manufacturing Cell Therapies
Figure 16.2. Centralized Manufacturing: Process Model
Figure 16.3. Decentralized Manufacturing: Process Model
Figure 16.4. Cell Therapy Manufacturing: Types of Manufacturers
Figure 16.5. Cell Therapy: Challenges and Drivers
Figure 16.6. Cell Therapies: Potency as Critical Quality Attribute
Figure 16.7. Cell Therapy Manufacturing: Supply Chain Model
Figure 16.8. Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 17.1. Targeted Therapies: Pricing Model based on Patient Segment
Figure 18.1. Overall T-Cell Immunotherapies Market, 2019-2030 (USD Billion)
Figure 18.2. T-Cell Immunotherapies Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Figure 18.3. T-Cell Immunotherapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Figure 18.4. T-Cell Immunotherapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Figure 18.5. T-Cell Immunotherapies Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
Figure 18.6. T-Cell Immunotherapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 18.7. Overall CAR-T Cell Therapies Market, 2019-2030 (USD Million)
Figure 18.8. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Million)
Figure 18.9. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Million)
Figure 18.10. CAR-T Cell Therapies Market: Distribution by Key Players (USD Million)
Figure 18.11. CAR-T Cell Therapies Market: Distribution by Target Geography (USD Million)
Figure 18.12. KYMRIAH® (Novartis): Current Status of Development
Figure 18.13. KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 18.14. YESCARTA® (Gilead Sciences): Current Status of Development
Figure 18.15. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 18.16. bb2121 (bluebird bio / Celgene): Current Status of Development
Figure 18.17. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030 (USD Million)
Figure 18.18. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen): Current Status of Development
Figure 18.19. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
Figure 18.20. MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 18.21. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 18.22. CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 18.23. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 18.24. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
Figure 18.25. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
Figure 18.26. AUTO2 (Autolus): Current Status of Development
Figure 18.27. AUTO2 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.28. AUTO3 (Autolus): Current Status of Development
Figure 18.29. AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.30. GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 18.31. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 18.32. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.33. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.34. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.35. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.36. CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 18.37. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 18.38. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 18.39. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.40. PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 18.41. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.42. TBI-1501 (Takara Bio): Current Status of Development
Figure 18.43. TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.44. IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 18.45. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.46. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 18.47. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 18.48. BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 18.49. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 18.50. CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 18.51. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 18.52. EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
Figure 18.53. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.54. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 18.55. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.56. Overall TCR-based Therapies Market, 2019-2030 (USD Million)
Figure 18.57. TCR-based Therapies Market: Distribution by Target Indication(s) (USD Million)
Figure 18.58. TCR-based Therapies Market: Distribution by Target Antigen(s) (USD Million)
Figure 18.59. TCR-based Therapies Market: Distribution by Key Players (USD Million)
Figure 18.60. TCR-based Therapies Market: Distribution by Target Geography (USD Million)
Figure 18.61. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current Status of Development
Figure 18.62. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030 (USD Million)
Figure 18.63. IMCgp100 (Immunocore): Current Status of Development
Figure 18.64. IMCgp100 (Immunocore) Sales Forecast, till 2030 (USD Million)
Figure 18.65. TBI-1301 (Takara Bio): Current Status of Development
Figure 18.66. TBI-1301 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.67. ALT-801 (Altor Bioscience): Current Status of Development
Figure 18.68. ALT-801 (Altor Bioscience) Sales Forecast, till 2030 (USD Million)
Figure 18.69. JTCR016 (Juno Therapeutics): Current Status of Development
Figure 18.70. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.71. LioCyx (Lion TCR): Current Status of Development
Figure 18.72. LioCyx (Lion TCR) Sales Forecast, till 2030 (USD Million)
Figure 18.73. Overall TIL-based Therapies Market, 2019-2030 (USD Million)
Figure 18.74. TIL-based Therapies Market: Distribution by Target Indication(s) (USD Million)
Figure 18.75. TIL-based Therapies Market: Distribution by Key Players (USD Million)
Figure 18.76. TIL-based Therapies Market: Distribution by Target Geography (USD Million)
Figure 18.77. TILs (Nantes University Hospital): Current Status of Development
Figure 18.78. TILs (Nantes University Hospital) Sales Forecast, till 2030 (USD Million)
Figure 18.79. TILs (Netherlands Cancer Institute): Current Status of Development
Figure 18.80. TILs (Netherlands Cancer Institute) Sales Forecast, till 2030 (USD Million)
Figure 18.81. Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
Figure 18.82. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.83. LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 18.84. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.85. LTX-315 and TILs (Lytix Biopharma): Current Status of Development
Figure 18.86. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030 (USD Million)
Figure 19.1. Different Channels Used for Promotional Campaigns
Figure 19.2. Promotional / Marketing Strategy: Product Website Analysis
Figure 19.3. Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 19.4. Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 19.5. Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 19.6. Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 19.7. KYMRIAH®, Presence in Conferences
Figure 19.8. Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
Figure 19.9. Product Website Analysis: YESCARTA®, Messages for Patients
Figure 19.10. Product Website Analysis: YESCARTA®, Kite Konnect™
Figure 19.11. Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
Figure 19.12. YESCARTA®, Presence in Conferences
Figure 21.1. T-Cell Immunotherapies Market Landscape: Industry Participants
Figure 21.2. T-Cell Immunotherapies Market Landscape: Non-Industry Participants
Figure 21.3. T-Cell Immunotherapies Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Tables

Table 3.1. Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2. FDA Approved Antibody based Cancer Therapeutics
Table 3.5. Key Characteristics of CAR-T Cells
Table 3.6. Comparison of First and Second-Generation CAR-T Cells
Table 3.7. CD19 CAR-T Cells: Preclinical Results
Table 3.8. Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9. CAR-T Cell and TCR-based Therapies: Key Differences
Table 5.1. T-Cell Immunotherapies: Clinical Pipeline
Table 5.2. T-Cell Immunotherapies: Preclinical Pipeline
Table 6.1. CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2. CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3. BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4. BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5. Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6. Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7. GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8. GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9. CAR-T Cell Immunotherapies: Principle Investigators
Table 6.10. TCR-based Immunotherapies: Principle Investigators
Table 6.11. TIL-based Immunotherapies: Principle Investigators
Table 6.12. CAR-T Cell Therapies: Information on Constructs of Clinical Candidates
Table 7.1. CAR-T Cell Immunotherapies: List of Clinical Trials
Table 8.1. KYMRIAH®: Clinical Studies
Table 8.2. KYMRIAH®: Clinical Trial Endpoints (Acute Lymphoblastic Leukemia)
Table 8.3. KYMRIAH®: Clinical Trial Endpoints (Chronic Lymphocytic Leukemia / Multiple Myeloma / Non-Hodgkin Lymphoma)
Table 8.4. YESCARTA®: Clinical Studies
Table 8.5. YESCARTA®: Clinical Trial Endpoints
Table 8.6. JCAR Series: Molecules in Clinical Development
Table 8.7. JCAR Series: CAR-T Design
Table 8.8. JCAR014: Clinical Studies
Table 8.9. JCAR017: Clinical Studies
Table 8.10. JCAR018: Clinical Studies
Table 8.11. JCAR020: Clinical Studies
Table 8.12. JCAR023: Clinical Studies
Table 8.13. JCAR024: Clinical Studies
Table 8.14. JCARH125: Clinical Studies
Table 8.15. JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.16. JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.17. JCAR Series: Dosage Regimen
Table 8.18. bb2121: Clinical Studies
Table 8.19. bb2121: Clinical Trial Endpoints
Table 8.20. LCAR-B38M CAR-T: Clinical Studies
Table 8.21. LCAR-B38M CAR-T: Clinical Trial Endpoints
Table 8.22. Takara Bio’s CD19 CAR-T Cell Therapy: Clinical Studies
Table 8.23. Takara Bio’s CD19 CAR-T Cell Therapy: Clinical Trial Endpoints
Table 8.24. TBI-1501: Dosage Regimen
Table 8.25. AUTO2: Clinical Studies
Table 8.26. AUTO3: Clinical Studies
Table 8.27. Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.28. Sinobioway Cell Therapy’s CD19 CAR-T Cell Therapy: Clinical Studies
Table 8.29. Sinobioway Cell Therapy’s EPCAM CAR-T Cell Therapy: Clinical Studies
Table 8.30. Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31. Phase I/II or Phase II CAR-T Therapies from the Industry Players
Table 9.1. NY-ESO TCR: Clinical Studies
Table 9.2. MAGE-A10: Clinical Studies
Table 9.3. MAGE A-4: Current Status of Development
Table 9.4. AFP T-Cell: Current Status of Development
Table 9.5. NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
Table 9.6. MAGE A-10 / MAGE A-4 / AFP TCR: Clinical Trial Endpoints
Table 9.7. IMCgp100: Clinical Studies
Table 9.7. IMCgp100: Clinical Trial Endpoints
Table 9.8. ALT-801: Clinical Studies
Table 9.9. ALT-801: Clinical Trial Endpoints
Table 9.10. JTCR016: Clinical Studies
Table 9.11. JTCR016: Clinical Trial Endpoints
Table 9.12. WT1 TCR: Clinical Studies
Table 9.13. WT1 TCR: Clinical Trial Endpoints
Table 9.14. TBI-1301: Clinical Studies
Table 9.15. TBI-1301: Clinical Trial Endpoints
Table 10.1. LN-144: Current Status of Development
Table 10.2. LN-144: Clinical Trial Endpoints
Table 10.3. LN-144: Patent Portfolio
Table 10.4. LN-145: Current Status of Development
Table 10.5. LN-145: Clinical Trial Endpoints
Table 10.6. Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 10.7. Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 11.1. Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 11.2. Leukemia: List of Marketed Targeted Therapeutics
Table 11.3. Lymphoma: List of Marketed Targeted Therapeutics
Table 11.4. T-Cell Immunotherapies: Targets under Investigation for Leukemia
Table 11.5. T-Cell Immunotherapies: Targets under Investigation for Lymphoma
Table 11.6. Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 11.7. T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
Table 11.8. Melanoma: List of Marketed Targeted Therapeutics
Table 11.9. TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
Table 11.10. T-Cell Immunotherapies: TIL Therapies under Investigation for Metastatic Melanoma
Table 11.11. Lung Cancer: List of Marketed Targeted Therapeutics
Table 11.12. T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
Table 11.13. Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 11.14. T-Cell Immunotherapies: Targets under Investigation for Pancreatic Cancer
Table 11.15. Liver Cancer: List of Marketed Targeted Therapeutics
Table 11.16. CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 11.17. TCR-based Therapies: Targets under Investigation for Liver Cancer
Table 11.18. Breast Cancer: List of Marketed Targeted Therapeutics
Table 11.19. CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 11.20. TCR-based Therapies: Targets under Investigation for Breast Cancer
Table 11.21. Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 11.22. T-Cell Immunotherapies: Targets under Investigation for Ovarian Cancer
Table 11.23. Bladder Cancer: List of Marketed Targeted Therapeutics
Table 11.24. Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 12.1. Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 12.2. Editas Medicine: Funding Instances
Table 12.3. Editas Medicine: Collaborations
Table 12.4. Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 12.5. Intellia Therapeutics: Funding Instances
Table 12.6. Intellia Therapeutics: Collaborations
Table 12.7. CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
Table 12.8. CRISPR Therapeutics: Funding Instances
Table 12.9. CRISPR Therapeutics: Collaborations
Table 12.10. Beam Therapeutics: Funding Instances
Table 12.11. Beam Therapeutics: Collaborations
Table 12.12. Gracell Biotechnologies: Funding Instances
Table 12.13. Cellectis: Funding Instances
Table 12.14. Cellectis: Collaborations
Table 12.15. bluebird bio: megaTAL Technology, Research Publications
Table 12.16. bluebird bio: Funding Instances
Table 12.17. bluebird bio: Collaborations
Table 12.18. Sangamo Therapeutics: Funding Instances
Table 12.19. Sangamo Therapeutics: Collaborations
Table 12.20. Unum Therapeutics: Funding Instances
Table 12.21. Unum Therapeutics: Collaborations
Table 12.22. Celyad: Funding Instances
Table 12.23. Celyad: Collaborations
Table 12.24. Glycostem: Funding Instances
Table 12.25. Glycostem: Collaborations
Table 12.26. Intrexon: Funding Instances
Table 12.27. Intrexon: Collaborations
Table 12.28. Bellicum Pharmaceuticals: Key Switch Technologies
Table 12.29. Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 12.30. Bellicum Pharmaceuticals: Funding Instances
Table 12.31. Bellicum Pharmaceuticals: Collaborations
Table 12.32. Theravectys: Funding Instances
Table 12.33. CAR-T Cell Therapy Technologies for Safety Enhancement
Table 12.34. Formula Pharmaceuticals: Collaborations
Table 13.1. T-Cell Immunotherapies: Partnerships and Collaborations, 2005-2019
Table 14.1. T-Cell Immunotherapies: Funding and Investments, Pre-2009-2017
Table 14.2. T-Cell Immunotherapies: Summary of Investments
Table 15.1. List of Other T-Cell Immunotherapies
Table 15.2. Treg Cells: Properties
Table 16.1. Assessment Strategies for Different Manufacturing Processes
Table 16.2. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 16.3. Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 16.4. Cell Therapy Manufacturing: Contract Manufacturers
Table 17.1. Price of Marketed Cell / Gene Therapies
Table 17.2. Price of Marketed Targeted Drugs
Table 17.3. T-Cell Immunotherapies: Expert Opinions on Pricing
Table 17.4. CAR-T Cell Therapies: Reimbursement Landscape
Table 18.1. T-Cell Immunotherapies: List of Forecasted Molecules
Table 18.2. T-Cell Immunotherapies Market: Value Creation Analysis
Table 19.1. KYMRIAH®: Drug Overview
Table 19.2. YESCARTA®: Drug Overview
Table 20.1. Adaptimmune Therapeutics: Company Profile
Table 20.2. Autolus: Company Profile
Table 20.3. bluebird bio: Company Profile
Table 20.4. CARsgen Therapeutics: Company Profile
Table 20.5. Celgene: Company Profile
Table 20.6. Cell Medica: Company Profile
Table 20.7. Cellectis: Company Profile
Table 20.8. Cellular Biomedicine Group: Company Profile
Table 20.9. Immunocore: Company Profile
Table 20.10. Innovative Cellular Therapeutics: Company Profile
Table 20.11. Iovance Biotherapeutics: Company Profile
Table 20.12. Kite Pharma: Company Profile
Table 20.13. Lion TCR: Company Profile
Table 20.14. Noile-Immune Biotech: Company Profile
Table 20.15. Novartis: Company Profile
Table 20.16. Shanghai GeneChem: Company Profile
Table 20.17. Sinobioway Cell Therapy: Company Profile
Table 20.18. Takara Bio: Company Profile
Table 20.19. Unum Therapeutics: Company Profile
Table 20.20. ZIOPHARM Oncology: Company Profile
Table 23.1. T-Cell Immunotherapies: Analysis by Type of Product
Table 23.2. T-Cell Immunotherapies: Analysis by Type of Developer
Table 23.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
Table 23.4. T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
Table 23.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
Table 23.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
Table 23.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
Table 23.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
Table 23.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
Table 23.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
Table 23.13. TCR-based Immunotherapies: Analysis by Target Antigen
Table 23.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
Table 23.16. T-Cell Immunotherapies: Analysis by Route of Administration
Table 23.17. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
Table 23.18. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
Table 23.19. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 23.20. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 23.21. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 23.22. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
Table 23.23. T-Cell Immunotherapies: Popular Targets in Solid Tumor
Table 23.24. CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 23.25. CAR-Construction: Analysis by Type scFv Antibody used in CAR-T Therapies
Table 23.26. CAR-Construction: Analysis by Type of Vector
Table 23.27. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 23.28. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 23.29. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 23.30. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
Table 23.31. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
Table 23.32. Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.33. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Table 23.34. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 23.35. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Table 23.36. Partnerships and Collaborations: Distribution by Type of Industry
Table 23.37. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
Table 23.38. Partnerships and Collaborations: Distribution by Individual Products
Table 23.39. Most Active Industry Players: Distribution by Number of Partnerships
Table 23.40. Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 23.41. Most Active Contract Manufacturers: Distribution by Number of Manufacturing Agreements
Table 23.42. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Table 23.43. Partnerships and Collaborations: Regional Distribution
Table 23.44. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.45. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2009-2019
Table 23.46. Funding and Investment Analysis: Cumulative Amount Invested, Pre-2009-2019 (USD Million)
Table 23.47. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2009-2019
Table 23.48. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre-2009-2019 (USD Million)
Table 23.49. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Table 23.50. Most Active Players: Distribution by Number of Instances
Table 23.51. Most Active Investors: Distribution by Number of Instances
Table 23.52. Funding and Investment Analysis: Distribution by Geography
Table 23.53. Other T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.54. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.55. Other T-Cell Immunotherapies: Analysis by Type of Cells
Table 23.56. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.57. Overall T-Cell Immunotherapies Market, 2019-2030: Conservative Scenario (USD Billion)
Table 23.58. Overall T-Cell Immunotherapies Market, 2019-2030: Base Scenario (USD Billion)
Table 23.59. Overall T-Cell Immunotherapies Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 23.60. T-Cell Immunotherapies Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Table 23.61. T-Cell Immunotherapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.62. T-Cell Immunotherapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Table 23.63. T-Cell Immunotherapies Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
Table 23.64. T-Cell Immunotherapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.65. Overall CAR-T Cell Therapies Market, 2019-2030: Conservative Scenario (USD Million)
Table 23.66. Overall CAR-T Cell Therapies Market, 2019-2030: Base Scenario (USD Million)
Table 23.67. Overall CAR-T Cell Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
Table 23.68. CAR-T Cell Therapies Market: Distribution by Target Indications (USD Million)
Table 23.69. CAR-T Cell Therapies Market: Distribution by Target Antigens (USD Million)
Table 23.70. CAR-T Cell Therapies Market: Distribution by Key Players (USD Million)
Table 23.71. CAR-T Cell Therapies Market: Distribution by Target Geography (USD Million)
Table 23.72. KYMRIAH® (Novartis) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.73. KYMRIAH® (Novartis) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.74. KYMRIAH® (Novartis) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.75. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.76. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.77. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.78. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.79. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.80. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.82. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.83. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.84. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.85. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.86. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.87. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.88. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.89. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.90. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.91. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.92. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.93. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.94. AUTO2 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.95. AUTO2 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.96. AUTO2 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.97. AUTO3 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.98. AUTO3 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.99. AUTO3 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.100. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.101. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.102. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.103. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.104. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.105. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.106. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.107. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.108. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.109. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.110. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.111. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.112. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.113. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.114. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.115. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.116. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.117. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.118. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.119. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.120. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.121. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.122. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.123. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.124. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.125. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.126. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.127. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.128. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.129. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.130. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.131. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.132. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.133. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.134. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.135. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.136. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.137. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.138. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.139. Overall TCR-based Therapies Market, 2019-2030: Conservative Scenario (USD Million)
Table 23.140. Overall TCR-based Therapies Market, 2019-2030: Base Scenario (USD Million)
Table 23.141. Overall TCR-based Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
Table 23.142. TCR-based Therapies Market: Distribution by Target Indications (USD Million)
Table 23.143. TCR-based Therapies Market: Distribution by Target Antigens (USD Million)
Table 23.144. TCR-based Therapies Market: Distribution by Key Players (USD Million)
Table 23.145. TCR-based Therapies Market: Distribution by Target Geography (USD Million)
Table 23.146. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.147. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.148. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.149. IMCgp100 (Immunocore) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.150. IMCgp100 (Immunocore) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.151. IMCgp100 (Immunocore) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.152. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.153. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.154. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.155. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.156. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.157. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.158. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.159. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.160. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.161. LioCyx (Lion TCR) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.162. LioCyx (Lion TCR) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.163. LioCyx (Lion TCR) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.164. Overall TIL-based Therapies Market, 2019-2030: Conservative Scenario (USD Million)
Table 23.165. Overall TIL-based Therapies Market, 2019-2030: Base Scenario (USD Million)
Table 23.166. Overall TIL-based Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
Table 23.167. TIL-based Therapies Market: Distribution by Target Indication(s) (USD Million)
Table 23.168. TIL-based Therapies Market: Distribution by Key Players (USD Million)
Table 23.169. TIL-based Therapies Market: Distribution by Target Geography (USD Million)
Table 23.170. TILs (Nantes University Hospital) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.171. TILs (Nantes University Hospital) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.172. TILs (Nantes University Hospital) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.173. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.174. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.175. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.176. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.177. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.178. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.179. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.180. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.181. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.182. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.183. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.184. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030s: Optimistic Scenario (USD Million)
Table 23.185. T-Cell Immunotherapies Market Forecast, 2019, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3P Biopharmaceuticals
  • A*STAR’s Genome Institute of Singapore
  • AbbVie Ventures
  • AbCheck
  • AbClon
  • Abingworth
  • Abramson Cancer Center
  • AbVitro
  • ACEA Biosciences
  • Acer Therapeutics
  • Acerta Pharma
  • Acorn Pacific Ventures
  • Adage Capital Management
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Adimab
  • Advanced BioScience Laboratories
  • Advent Bioservices
  • Adverum Biotechnologies
  • Aeon Therapeutics
  • Affiliated Hospital to Academy of Military Medical Sciences
  • AFG Private Equity
  • Agent Capital
  • AgenTus Therapeutics
  • AGF Private Equity
  • Agreen Biotech
  • Aisling Capital
  • AK (Suzhou) Biomedical
  • Akron Biotech
  • Alaska Permanent Fund
  • Albert Einstein College of Medicine
  • Alberta Cell Therapy Manufacturing
  • Alexandria Venture Investments
  • Allele Biotechnology and Pharmaceuticals
  • Allergan
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Alpine Immune Sciences
  • Alta Partners
  • Altor BioScience
  • Amgen
  • Amsterdam BioTherapeutics Unit
  • Andalusian Initiative for Advanced Therapies
  • Anhui Kedgene Biotechnology
  • Anhui Provincial Hospital
  • Antagene
  • Anterogen
  • Aokai Biotech
  • apceth Biopharma
  • Aquilo Capital Management
  • ARBELE
  • ARCH Venture Partners
  • Argos Therapeutics
  • ARIAD Pharmaceuticals
  • Arix Bioscience
  • ArrowMark Partners
  • Asahi Glass Company
  • Astellas Pharma
  • Asterias Biotherapeutics
  • AstraZeneca
  • Asymptote
  • AT Impf
  • Atara Biotherapeutics
  • Atlantic Bio GMP
  • Atlas Venture
  • Atossa Genetics
  • Atreca
  • Aurora Biopharma
  • Autolus
  • Avacta
  • AVICT Global Holdings
  • Baader Bank
  • Bambino Gesù Hospital
  • Bank Degroof Petercam
  • BankInvest Biomedical Venture
  • Barclays
  • Batavia Biosciences
  • Bausch Health
  • Bavarian Nordic
  • Baxalta
  • Bayer
  • Baylor College of Medicine
  • Be The Match BioTherapies
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing Genomics Institute
  • Beijing Immunochina Medical Science and Technology
  • Beijing Mario Biotechnology
  • Beijing Sanwater Biological Technology
  • Beijing You’an Hospital
  • Bellco Capital
  • Bellicum Pharmaceuticals
  • Beth Israel Deaconess Medical Center
  • Bezos Expeditions
  • Bill & Melinda Gates Foundation
  • Bio Elpida
  • BioAtla
  • Bioceltech Therapeutics
  • Biogen
  • Bioinova
  • BioLife Solutions
  • Biomedical Catalyst
  • BioNTech
  • bluebird bio
  • BMO Capital Markets
  • Boehringer Ingelheim
  • BofA Securities
  • Bone Therapeutics
  • Boston Children's Hospital
  • Boxer Capital
  • Brace Pharma Capital
  • Brammer Bio
  • Bristol-Myers Squibb
  • Cabaret Biotech
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine
  • Canaan Partners
  • Cancer Prevention Research Institute of Texas
  • Cancer Research UK
  • Cantor Fitzgerald
  • Capricor Therapeutics
  • Captain T Cell
  • Cardiff University
  • Caribou Biosciences
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Cartherics
  • Casdin Capital
  • Casebia Therapeutics
  • Celdara Medical
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Biotech
  • Cell Design Labs
  • Cell Medica
  • Cell Tech Pharmed
  • Cell Therapies
  • Cellectis
  • Cellenkos
  • CELLforCURE
  • Cellin Technologies
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Celyad
  • Center for Cell and Gene Therapy
  • Center for Cell Manufacturing Ireland, National University of Ireland Galway
  • Changhai Hospital
  • CHDI Foundation
  • Chengdu MedGenCell
  • Chengdu Miaoji Medical Technology
  • Chiesi Farmaceutici
  • Children's Hospital of Philadelphia
  • Children's Mercy Hospital
  • Children's Oncology Group
  • Children's Research Institute
  • China Immunotech
  • China Regenerative Medicine International
  • Chinese Academy of Sciences
  • Chinese PLA General Hospital
  • Christie NHS Foundation Trust
  • Citigroup
  • City of Hope National Medical Center
  • Clough Capital Partners
  • Cognate BioServices
  • Columbia University
  • Cook MyoSite
  • Cooperative Research Centre for Cell Therapy Manufacturing
  • Copenhagen University Hospital
  • Cormorant Asset Management
  • Cowen Private Investments
  • CRISPR Therapeutics
  • Cryoport
  • Cryosite
  • CTI Clinical Trial and Consulting Services
  • Curative Ventures
  • CureVac
  • Cystic Fibrosis Foundation Therapeutics
  • CytoLumina Technologies
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • Dangdai International Group
  • Dartmouth College
  • Deerfield Management
  • Delenex Therapeutics
  • Dendreon
  • Deutsche Bank Securities
  • DFJ Venture Capital
  • dievini Hopp Biotech
  • Direct Selling Association of Malaysia
  • Ditch Plains Capital Management
  • Dongguan People's Hospital
  • Dow AgroSciences
  • DS Asset Management
  • Duke Cancer Institute
  • EcoR1 Capital
  • Editas Medicine
  • Edmond de Rothschild Investment Partners
  • Efung Capital
  • Eli Lilly
  • Emory Personalized Immunotherapy Core
  • Endocyte
  • ERS Genomics
  • Eureka Therapeutics
  • European Commission
  • Eurostars
  • Eutilex
  • EXUMA Biotechnology
  • F-Prime Capital
  • F1 BioVentures
  • F1 Oncology
  • F2 Ventures
  • Fate Therapeutics
  • Fetolumina Technologies
  • Financière IDAT
  • Finnish Funding Agency for Technology and Innovation
  • First Affiliated Hospital of Chengdu Medical College
  • First Affiliated Hospital of Harbin Medical University
  • First Affiliated Hospital of Sun Yat-sen University
  • First Affiliated Hospital of Wenzhou Medical University
  • First Affiliated Hospital of Zhejiang University
  • First People's Hospital of Foshan
  • Five Prime Therapeutics
  • Five Rings Financial
  • Fondazione Telethon and Ospedale San Raffaele
  • Foresite Capital
  • Forevertek Biotechnology
  • Formula Pharmaceuticals
  • Fortress Biotech
  • Fosun Pharmaceutical
  • Franklin Templeton Investments
  • Fraunhofer Institute for Cell Therapy and Immunology
  • Fred Hutchinson Cancer Research Center
  • Friedreich’s Ataxia Research Alliance
  • Froceth
  • Fuda Cancer Hospital
  • Fudan University
  • Fujian Medical University
  • FUJIFILM Cellular Dynamics
  • G.N. Tech Venture Capital
  • Gadeta
  • Gamida Cell
  • GammaCell Bio-Technologies
  • GammaDelta Therapeutics
  • GE Healthcare Life Sciences
  • GenCure
  • Gene and Cell Therapy Lab
  • Genentech
  • Genmab
  • Genus Oncology
  • German Federal Ministry of Education and Research
  • Ghent University Hospital
  • GigaGen
  • Gilead Sciences
  • GlaxoSmithKline
  • Glycostem
  • Goldman Sachs
  • GP Capital
  • Gracell Biotechnologies
  • Green Cross Cell
  • Guangdong Xiangxue Precision Medical Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou Eighth People's Hospital
  • Guangzhou FineImmune Biotechnology
  • Guangzhou First People's Hospital
  • Guangzhou Xiangxue Pharmaceutical
  • Guangzhou Yiyang Biological Technology
  • Guggenheim Securities
  • Guy's and St Thomas' NHS Foundation Trust
  • H. Lee Moffitt Cancer Center and Research Institute
  • H.C. Wainwright
  • Hadassah Medical Center
  • Haitong International Securities
  • Hangzhou Cancer Hospital
  • Harbin Medical University
  • Harvard University
  • Hebei Senlang Biotechnology
  • Hebei Yanda Ludaopei Hospital
  • Helix BioPharma
  • Helixmith
  • Henan Cancer Hospital
  • Henan Hualong Biotechnology
  • Henan University of Traditional Chinese Medicine
  • HengRui YuanZheng Bio-Technology
  • Herlev Hospital
  • Hillhouse Capital Group
  • Histocell
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Horizon Discovery
  • Horizon Technology Finance
  • Howard Hughes Medical Institute
  • Hrain Biotechnology
  • Human Stem Cells Institute
  • Hunan Yongren Medical Innovation
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • Icell Kealex Therapeutics
  • ICON
  • Immatics Biotechnologies
  • Immune Therapeutics
  • Immunocore
  • Immunovative Therapies
  • Imperial College London
  • Imperial Innovations Group
  • Innovate UK
  • Innovative Cellular Therapeutics
  • Innovative Genomins Institute
  • Institut Curie
  • Institut Pasteur
  • Instituto de Salud Carlos III
  • Intellia Therapeutics
  • Intrexon
  • Invectys
  • Invesco Perpetual
  • Investing Women
  • Iovance Biotherapeutics
  • Iowa State University Research Foundation
  • J.P. Morgan Securities
  • Janssen Biotech
  • Janus Capital Management
  • Japan Science and Technology Agency
  • Jazz Pharmaceuticals
  • JCR Pharmaceuticals
  • Jefferies Group
  • Jennison Associates
  • Jiangsu Cancer Hospital
  • JIG Genesis Fountain Healthcare Ventures
  • JMP Group
  • John Goldman Centre for Cellular Therapy
  • Johns Hopkins University
  • Jolly Innovation Ventures
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • JW Biotechnology
  • KAEDI
  • Kaitai Capital
  • Karolinska University Hospital
  • Karst Peak Capital
  • KBI Biopharma
  • Keio University
  • Key Biologics
  • King's College London
  • Kington Capital
  • Kite Pharma
  • Kolon Investment
  • KTB Ventures
  • Laurion Capital Management
  • Leerink Partners
  • Legend Capital
  • Leiden University Medical Center
  • Leucid Bio
  • Level One Partners
  • Lexicon Pharmaceuticals
  • Life Technologies
  • LifeForce Capital
  • Lifeline Ventures
  • LifeSci Capital
  • Lightstone Ventures
  • Lilly Asia Ventures
  • Liminatus Pharma
  • Lincoln Park Capital Fund
  • Lion TCR
  • Living Pharmaceticals
  • Longitude Capital
  • Lonza
  • Loughborough University
  • Loyola University
  • Lucion Group
  • Lupus Ventures
  • LVC Super Unicorn Fund
  • Lytix Biopharma
  • Lübeck Institute of Experimental Dermatology
  • MabQuest
  • MabVax Therapeutics Holdings
  • Malin
  • Marino Biotechnology
  • Massachusetts General Hospital Cancer Center
  • MaSTherCell
  • Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • MaxCyte
  • Maxim Group
  • Mayo Clinic Ventures
  • MD Anderson Cancer Center
  • Medarex
  • Medical College of Wisconsin
  • Medicxi Ventures
  • Medigene
  • MedImmune
  • MEDINET
  • Medisix Therapeutics
  • Medpost Urgent Care
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merck Serono
  • Merlin Nexus
  • Mesoblast
  • Mie University
  • Millennium Pharmaceuticals (acquired by Takeda Oncology)
  • Miller Value Partners
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • MingJu Therapeutics Shanghai
  • Mirae Asset Financial Group
  • Mission Bay Capital
  • Moffitt Cancer Center
  • Molecular and Cellular Therapeutics
  • MolMed
  • Morgan Stanley
  • MPM Capital
  • MSD Partners
  • Mustang Bio
  • Nanfang Hospital of Southern Medical University
  • Nanjing Children's Hospital
  • Nanjing Drum Tower Hospital
  • Nanjing Legend Biotech
  • Nantes University Hospital
  • NantKwest
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • National University of Singapore
  • Navy General Hospital (Beijing)
  • NCL Innovation
  • Netherlands Cancer Institute
  • New Enterprise Associates
  • New Leaf Venture Partners
  • New York Medical College
  • Nextech Invest
  • Nikon CeLL innovation
  • Ningbo Cancer Hospital
  • Nipro
  • Nohla Therapeutics
  • Noile-Immune Biotech
  • Northland Capital Markets
  • Novadip Biosciences
  • Novartis
  • Novo Ventures
  • Oaktree Capital Management
  • Obsidian Therapeutics
  • OCV Partners
  • ODYSSEE Venture
  • Omega Funds
  • Oncodesign
  • OncoTracker
  • OnCyte
  • Ono Pharmaceutical
  • Onyx Pharmaceuticals
  • Opexa Therapeutics
  • Opus Bio
  • OrbiMed HealthCare Fund Management
  • Oriza Seed Capital
  • Osage University Partners
  • Oxford BioMedica
  • Oxford MEStar
  • PACT Pharma
  • Panacea Ventures
  • Parker Institute for Cancer Immunotherapy
  • PCI Services
  • PCT Cell Therapy Services
  • Peking University
  • Pentwater Capital Management
  • PeproMene Bio
  • Perceptive Advisors
  • PersonGen BioTherapeutics (Suzhou)
  • Peter MacCallum Cancer Centre
  • Peter Thiel
  • Petercam
  • Pfizer
  • PharmaBio
  • PharmaCell
  • Pharmicell
  • Phio Pharmaceuticals
  • Photon Fund
  • Ping An Ventures
  • Pinze Lifetechnology
  • Piper Jaffray
  • Pluristem Therapeutics
  • PolyBioCept
  • Pontifax
  • Poseida Therapeutics
  • Praxis Pharmaceutical
  • Precision BioSciences
  • Precision Genome Engineering
  • Princess Margaret Cancer Centre
  • ProMab Biotechnologies
  • Promethera Biosciences
  • Prometheus Laboratories
  • Provia Laboratories
  • Puma Biotechnology
  • PureTech Health
  • Qingzhe Capital
  • Quogue Capital
  • QVT Financial
  • RA Capital Management
  • Raymond James
  • Rayne Cell Therapy Suite
  • Redmile Group
  • RedoxTherapies (acquired by Juno Therapeutics)
  • Regeneron Pharmaceuticals
  • Relieve Genetics
  • Remeditex Ventures
  • Renji Hospital
  • Renmin Hospital of Wuhan University
  • Ridgeback Capital Management
  • Riyadh Pharma
  • Roche
  • Rockland Immunochemicals
  • Rockspring Capital
  • Roger Williams Medical Center
  • RoslinCT
  • Roswell Park Comprehensive Cancer Center
  • Royal Adelaide Hospital
  • RXi Pharmaceuticals
  • Sabby Management
  • Samsara BioCapital
  • San Raffaele Hospital
  • Sangamo Therapeutics
  • Sanofi-Genzyme BioVentures
  • Scotia Biologics
  • Scottish Investment Bank
  • Scottish National Blood Transfusion Service
  • Seattle Children's Hospital
  • Seattle Genetics
  • Second Affiliated Hospital of Guangzhou Medical University
  • Second Military Medical University
  • Sectoral Asset Management
  • Sequoia Capital China
  • Servier
  • Shanghai Bioray Laboratory
  • Shanghai Cell Therapy Engineering Technology Research Center
  • Shanghai Changzheng Hospital
  • Shanghai Chest Hospital
  • Shanghai Children's Medical Center
  • Shanghai GeneChem
  • Shanghai General Hospital
  • Shanghai Houchao Biotechnology
  • Shanghai iCELL Biotechnology
  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Longyao Biotechnology
  • Shanghai Sinobioway Sunterra Biotechnology
  • Shanghai Sunway Biotech
  • Shanghai Tongji Hospital
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Sheba Medical Center
  • ShengJing360
  • Shenzhen BinDeBio
  • Shenzhen Geno-Immune Medical Institute
  • Shenzhen Hornetcorn Biotechnology
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
  • Sherpa Venture Capital
  • Shionogi
  • Shire
  • Shiyu Capital
  • Shougang Fund
  • Sibiono GeneTech
  • Sichuan University
  • Sidney Kimmel Comprehensive Cancer Center
  • Sigma-Aldrich
  • Sinobioway Cell Therapy
  • Sirona Capital
  • SNU Bio Angel
  • Sorrento Therapeutics
  • SOTIO
  • Southwest General Health Center
  • Spark Therapeutics
  • SR One
  • St. George's Hospital
  • St. Jude Children’s Research Hospital
  • Stage Cell Therapeutics
  • Stanford University
  • Stem Cell Institute
  • Stifel
  • StrideBio
  • Sun Yat-sen University
  • SunTerra Capital
  • SunTrust Robinson Humphrey
  • Surveyor Capital
  • SVB Leerink
  • Symvivo
  • Syncona
  • SyndicateRoom
  • Synthace
  • T-Cell Factory (acquired by Kite Pharma)
  • T. Rowe Price Group
  • Tactiva Therapeutics
  • Taiho Ventures
  • Takara Bio
  • Takeda Pharmaceutical
  • Targazyme
  • Target ALS Foundation
  • Tavistock Group
  • TC BioPharm
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • Tekla Capital Management
  • Tel Aviv Sourasky Medical Center
  • Temasek
  • TeneoBio
  • Terumo Medical
  • Tesaro (acquired by GSK)
  • Tessa Therapeutics
  • Tethys Health Ventures
  • The Beijing Pregene Science and Technology
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
  • The First Affiliated Hospital of Guangzhou Medical University
  • The First Affiliated Hospital of Soochow University
  • The First People's Hospital of Lianyungang
  • The First People's Hospital of Yunnan
  • The Longevity Fund
  • The Ohio State University Comprehensive Cancer Center
  • The Pregene (ShenZhen) Biotechnology
  • The Research Council of Norway
  • The Second Xiangya Hospital of Central South University
  • The Third Affiliated Hospital of Southern Medical University
  • The University of Sydney
  • The University of Texas
  • The University of Utah
  • The Wistar Institute
  • Theravectys
  • Thermo Fisher Scientific
  • Thiel Capital
  • Third Military Medical University
  • Third Rock Ventures
  • Third Security
  • Three Arch Partners
  • Tianjin Medical University Cancer Institute and Hospital
  • Tianjin Mycure Medical Technology
  • TiGenix
  • TILT Biotherapeutics
  • Timmune Biotech
  • TissueGene-C
  • Tmunity Therapeutics
  • TNK Therapeutics
  • Tongji University School of Medicine
  • Touchstone Innovations
  • TRACT Therapeutics
  • TrakCel
  • Transgene
  • Transposagen Biopharmaceuticals
  • Triumvira Immunologics
  • TVAX Biomedical
  • TVM Capital
  • Two Blades Foundation
  • TxCell (acquired by Sangmo)
  • UBS
  • UNC Lineberger Comprehensive Cancer Center
  • Union Stem Cell & Gene Engineering
  • Universal Cells
  • University College London
  • University Health Network
  • University Hospital of Basel
  • University Medical Center Utrecht
  • University of Alberta
  • University of Birmingham
  • University of British Columbia
  • University of California
  • University of Florida
  • University of Lausanne
  • University of Manchester
  • University of Milano-Bicocca
  • University of Minnesota
  • University of North Carolina
  • University of Oxford
  • University of Pennsylvania
  • University of Rochester
  • University of Zurich
  • Unum Therapeutics
  • Uppsala University
  • Utrecht Holdings
  • Vaccinogen
  • Vecura
  • venBio
  • Venrock
  • Vericel
  • Versant Ventures
  • Vertex Pharmaceuticals
  • VGXI
  • Vi Ventures
  • Vical
  • Vida Ventures
  • ViGenCell
  • Viking Global Investors
  • Vineti
  • Vitruvian Networks
  • Vivo Capital
  • Waisman Biomanufacturing
  • Washington University
  • Wedbush Securities
  • Weill Cornell Medical College
  • Wellcome Trust
  • Wellington Management
  • Wells Fargo Securities
  • WH Partnership
  • White Rock Capital Management
  • William Blair
  • WindMIL Therapeutics
  • Woodford Investment Management
  • Wu Capital
  • Wuhan Sian Medical Technology
  • Wuhan Union Hospital
  • WuXi AppTec
  • X-Body
  • Xellbiogene
  • Xiangxue Life Sciences
  • Xiangxue Pharmaceutical
  • Xijing Hospital
  • Xinqiao Hospital
  • Xuzhou Medical University
  • Yake Biotechnology
  • Yale University
  • Yipu Capital
  • YuanMing Capital
  • Yuanyi Biotechnology
  • Zelluna Immunotherapy
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang University
  • Zhujiang Hospital
  • Ziopharm Oncology
Note: Product cover images may vary from those shown
Adroll
adroll